Daiichi Sankyo Presents Triple Combo Hypertension Results, Aims For No. 1 Combo Market Share
This article was originally published in PharmAsia News
Daiichi Sankyo May 8 announced results of a Phase III study showing that triple combination therapy of olmesartan, amlodipine and hydrochlorothiazide demonstrated significantly greater mean reduction in blood pressure compared to corresponding double combo therapy
You may also be interested in...
Daiichi Sankyo, Shionogi Profits Increase; Dainippon Sumitomo Expands In China - Japanese Pharma Earnings Roundup (Part 2 Of 2)
Major Japanese pharma face many of the same problems as major Western pharma, including patent cliffs and growth slowdown in traditional markets. Japanese pharma, on the other hand, have been slower to establish themselves in emerging markets. But that may soon be changing, as can be seen in this Japanese pharma earnings roundup, a periodic feature in PharmAsia News. Part one of this roundup looked at the approaches Astellas and Eisai are taking to deal with major patent losses (PharmAsia News, May 25, 2010).
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).